Abbott is launching a COVID-19 immunoglobulin M (IgM) lab-based antibody test to complement the immunoglobulin G (IgG) test it launched in April.
On 12 October, the company announced that the US Food and Drug Administration has granted an emergency use authorization for the new IgM test to run on Abbott’s Architect...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?